HomeOpen Access NewsSH MC Services

SH MC Services

Changing the treatment paradigm in Inflammatory Bowel Diseases

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.

No posts to display

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders